{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:43:05Z","timestamp":1762270985320},"reference-count":35,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.ejphar.2006.07.017","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T13:13:33Z","timestamp":1153919613000},"page":"82-87","source":"Crossref","is-referenced-by-count":54,"title":["The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets"],"prefix":"10.1016","volume":"546","author":[{"given":"Sarah","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Stockwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Carminati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2006.07.017_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib2","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","article-title":"Translating A2A antagonist KW6002 from animal models to parkinsonian patients","volume":"61","author":"Chase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.npp.1300444","article-title":"Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats","volume":"29","author":"Coccurello","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(96)00944-2","article-title":"Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats","volume":"321","author":"Fenu","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2005.06.035","article-title":"Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat","volume":"520","author":"Floran","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/JMN:26:2-3:209","article-title":"Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function","volume":"26","author":"Fuxe","year":"2005","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2006.07.017_bib7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1046\/j.0953-816x.2001.01759.x","article-title":"Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate\u2013putamen of rats","volume":"14","author":"Hauber","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2006.07.017_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","article-title":"Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience","volume":"22","author":"Hauser","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejphar.2006.07.017_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib11","first-page":"227","article-title":"Parkinson's disease therapy: treatment of early and late disease","volume":"114","author":"Jankovic","year":"2001","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.ejphar.2006.07.017_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.14.6.729","article-title":"Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease","volume":"14","author":"Jenner","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2006.07.017_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset","volume":"50","author":"Jenner","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2006.07.017_bib14","series-title":"Adenosine Receptors and Parkinson's Disease","first-page":"211","article-title":"Actions of adenosine antagonists in primate model of Parkinson's disease","author":"Kanda","year":"2000"},{"key":"10.1016\/j.ejphar.2006.07.017_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib16","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/00001756-199808240-00032","article-title":"Adenosine A2A receptors modify motor function in MPTP-treated common marmosets","volume":"9","author":"Kanda","year":"1998","journal-title":"NeuroReport"},{"key":"10.1016\/j.ejphar.2006.07.017_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1271\/bbb.65.1447","article-title":"New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia","volume":"65","author":"Kase","year":"2001","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.ejphar.2006.07.017_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1476-5381.1994.tb16171.x","article-title":"Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release","volume":"113","author":"Kurokawa","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib21","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1021\/jm058018d","article-title":"2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization","volume":"48","author":"Minetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2006.07.017_bib22","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease","volume":"20","author":"Nash","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2006.07.017_bib23","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.61.6_suppl_3.S24","article-title":"Present and future directions in the management of motor complications in patients with advanced PD","volume":"61","author":"Olanow","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2006.07.017_bib25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1460-9568.1996.tb01285.x","article-title":"Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats","volume":"8","author":"Pinna","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2006.07.017_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2005.01.057","article-title":"New adenosine A2A receptor antagonists: actions on Parkinson's disease models","volume":"512","author":"Pinna","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.07.017_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0893-133X(01)00256-1","article-title":"The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors","volume":"25","author":"Popoli","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2006.07.017_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1471-4159.2004.02887.x","article-title":"Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum","volume":"92","author":"Rodrigues","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2006.07.017_bib29","unstructured":"Rose, S., Croft, N., Jenner, P., in press. The novel adenosine antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in unilaterally 6-OHDA lesioned rats. Brain Res."},{"key":"10.1016\/j.ejphar.2006.07.017_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2006.07.017_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(91)90391-6","article-title":"Distribution of adenosine A2 receptor mRNA in the human brain","volume":"130","author":"Schiffmann","year":"1991","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2006.07.017_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870110203","article-title":"An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets","volume":"11","author":"Smith","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2006.07.017_bib33","unstructured":"Stasi, M., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M., Minetti, P., Ghirardi, O., Carminati, P., in press. ST1535: A preferential A2a adenosine receptor antagonist. Int. J. Neuropsychopharm. [Epublication ahead of print]."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2006.07.017_bib34","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1353-8020(03)00021-X","article-title":"Prevention and treatment of motor fluctuations","volume":"9","author":"Stocchi","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2006.07.017_bib35","series-title":"Adenosine Receptors and Parkinson's Disease","first-page":"229","article-title":"Selective adenosine A2a receptor antagonism as an alternative therapy for Parkinson's disease: a study in non-human primates","author":"Tadj Tahar","year":"2000"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429990600762X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429990600762X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T08:09:52Z","timestamp":1555747792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429990600762X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":35,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S001429990600762X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2006.07.017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}